APNHY
Price
$6.60
Change
+$0.03 (+0.46%)
Updated
May 21 closing price
Capitalization
4.83B
BIOVF
Price
$30.29
Change
-$0.21 (-0.69%)
Updated
May 23 closing price
Capitalization
5.81B
Interact to see
Advertisement

APNHY vs BIOVF

Header iconAPNHY vs BIOVF Comparison
Open Charts APNHY vs BIOVFBanner chart's image
Aspen Pharmacare Holdings
Price$6.60
Change+$0.03 (+0.46%)
Volume$449
Capitalization4.83B
Swedish Orphan Biovitrum AB
Price$30.29
Change-$0.21 (-0.69%)
Volume$4K
Capitalization5.81B
APNHY vs BIOVF Comparison Chart
Loading...
View a ticker or compare two or three
VS
APNHY vs. BIOVF commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APNHY is a Hold and BIOVF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (APNHY: $6.60 vs. BIOVF: $30.50)
Brand notoriety: APNHY and BIOVF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: APNHY: 27% vs. BIOVF: 225%
Market capitalization -- APNHY: $4.83B vs. BIOVF: $5.81B
APNHY [@Pharmaceuticals: Other] is valued at $4.83B. BIOVF’s [@Pharmaceuticals: Other] market capitalization is $5.81B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APNHY’s FA Score shows that 1 FA rating(s) are green whileBIOVF’s FA Score has 0 green FA rating(s).

  • APNHY’s FA Score: 1 green, 4 red.
  • BIOVF’s FA Score: 0 green, 5 red.
According to our system of comparison, BIOVF is a better buy in the long-term than APNHY.

Price Growth

APNHY (@Pharmaceuticals: Other) experienced а +0.15% price change this week, while BIOVF (@Pharmaceuticals: Other) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.70%. For the same industry, the average monthly price growth was +10.85%, and the average quarterly price growth was +39.68%.

Reported Earning Dates

APNHY is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.70% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

FUNDAMENTALS
Fundamentals
BIOVF($5.81B) has a higher market cap than APNHY($4.83B). BIOVF has higher P/E ratio than APNHY: BIOVF (19.92) vs APNHY (14.73). BIOVF YTD gains are higher at: 9.508 vs. APNHY (-20.097). APNHY has higher annual earnings (EBITDA): 7.98B vs. BIOVF (6.96B). APNHY has more cash in the bank: 8.05B vs. BIOVF (790M). APNHY has less debt than BIOVF: APNHY (26.8B) vs BIOVF (28.2B). APNHY has higher revenues than BIOVF: APNHY (38.4B) vs BIOVF (20.1B).
APNHYBIOVFAPNHY / BIOVF
Capitalization4.83B5.81B83%
EBITDA7.98B6.96B115%
Gain YTD-20.0979.508-211%
P/E Ratio14.7319.9274%
Revenue38.4B20.1B191%
Total Cash8.05B790M1,018%
Total Debt26.8B28.2B95%
FUNDAMENTALS RATINGS
APNHY vs BIOVF: Fundamental Ratings
APNHY
BIOVF
OUTLOOK RATING
1..100
334
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
77
Overvalued
PROFIT vs RISK RATING
1..100
8739
SMR RATING
1..100
10065
PRICE GROWTH RATING
1..100
9146
P/E GROWTH RATING
1..100
9190
SEASONALITY SCORE
1..100
8512

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APNHY's Valuation (12) in the null industry is somewhat better than the same rating for BIOVF (77). This means that APNHY’s stock grew somewhat faster than BIOVF’s over the last 12 months.

BIOVF's Profit vs Risk Rating (39) in the null industry is somewhat better than the same rating for APNHY (87). This means that BIOVF’s stock grew somewhat faster than APNHY’s over the last 12 months.

BIOVF's SMR Rating (65) in the null industry is somewhat better than the same rating for APNHY (100). This means that BIOVF’s stock grew somewhat faster than APNHY’s over the last 12 months.

BIOVF's Price Growth Rating (46) in the null industry is somewhat better than the same rating for APNHY (91). This means that BIOVF’s stock grew somewhat faster than APNHY’s over the last 12 months.

BIOVF's P/E Growth Rating (90) in the null industry is in the same range as APNHY (91). This means that BIOVF’s stock grew similarly to APNHY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
READX13.100.04
+0.31%
Lazard Emerging Markets Eq Advtg R6
SSMAX9.58N/A
N/A
SEI Small/Mid Cap Equity A (SIIT)
TIOTX15.83N/A
N/A
Nuveen International Opps Retire
PEDGX12.54N/A
N/A
Principal Edge MidCap Institutional
PAFDX34.91-0.08
-0.23%
T. Rowe Price Equity Income Advisor

APNHY and

Correlation & Price change

A.I.dvisor tells us that APNHY and TRUFF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APNHY and TRUFF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APNHY
1D Price
Change %
APNHY100%
N/A
TRUFF - APNHY
21%
Poorly correlated
-3.23%
NXSCF - APNHY
20%
Poorly correlated
N/A
PRFX - APNHY
20%
Poorly correlated
+1.03%
ESALF - APNHY
20%
Poorly correlated
N/A
SDZNY - APNHY
20%
Poorly correlated
+1.61%
More

BIOVF and

Correlation & Price change

A.I.dvisor tells us that BIOVF and INNPF have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOVF and INNPF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOVF
1D Price
Change %
BIOVF100%
-0.69%
INNPF - BIOVF
20%
Poorly correlated
-0.68%
APNHY - BIOVF
19%
Poorly correlated
N/A
BIOGY - BIOVF
11%
Poorly correlated
N/A
BOIRF - BIOVF
1%
Poorly correlated
N/A
ARSUF - BIOVF
1%
Poorly correlated
N/A
More